Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$1.93M+313.20%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brian Carrico
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 24
- Beta
- 1.45
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 5.36
Financials
Revenue
$1.93M+313.2%Net Income
$-2.28MEBITDA
$-2.05MFree Cash Flow
$-1.04MEPS (diluted)
$-0.19Shares Outstanding (diluted)
12.12M+125.2%Operating Expenses
$3.78MCash & Debt
$8.32MReturn of Capital
$25.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.57M | $-7.80M | $-0.95 |
| 2024 | $2.69M | $-8.24M | $-1.22 |
| 2023 | $2.46M | $-14.63M | $-2.32 |
| 2022 | $2.68M | $-4.78M | $-0.57 |
| 2021 | $2.72M | $-3.03M | $-0.62 |
| 2020 | $1.93M | $-3.73M | $-0.80 |
Valuation
NRXShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-28.57%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·7d ago·Neutral
NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced the appointment of Craig Blanchard as Chief Commercial Officer.
View source ↗ - Newsglobenewswire.com·20d ago·Negative
…ding Access to Over 18 million additional Covered Lives CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation (“PENFS”).
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
…e in the Lytham Partners Fall 2026 Investor Conference CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.
View source ↗ - Newszacks.com·20d ago·Positive
Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock? NRXS is benefiting from stronger IB-Stim volumes, broader reimbursement and VA access, but incomplete payer coverage and cash needs remain challenges.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
NeurAxis, Inc. (NRXS) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript NeurAxis, Inc. (NRXS) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript
View source ↗ - Newszacks.com·52d ago·Positive
NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up NeurAxis delivers record second-quarter 2026 revenues as stronger IB-Stim demand, higher pricing and an improved reimbursement mix lift gross margin.
View source ↗ - Newsseekingalpha.com·55d ago·Positive
NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.21 per share
Typical surprise -15.8% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.19 vs $-0.32beat
- Tue, May 12$-0.18 vs $-0.19beat
- Thu, Mar 19$-0.17 vs $-0.21beat
- Mon, Nov 10$-0.24 vs $-0.20miss
- Tue, Aug 12$-0.22 vs $-0.19miss
- Mon, May 12$-0.31 vs $-0.24miss
Estimates and results for NRXS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NRXS officers and directors.
- Bought
- $1.0m
- Sold
- $652k
4 trades
1 trade
- Henrichs Timothy Robertbought
- Carrico Thomas Joesephbought
- Carrico Brian Allenbought
- Aharon Gilbought
- Masimo Corpsold
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NRXS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.